Hemostemix Inc.
HEM
Classement en actions
#32860
Hemostemix Inc., a clinical stage biotechnology company, develops,... Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Prix de l'action
$0.04036653
Dernière synchronisation: 2026-10-20
Capitalisation boursière
$8.54M
Changement (1 jour)
0.00%
Changement (1 an)
-44.48%
Pays
CA
Échange Hemostemix Inc. (HEM)
Catégorie
Healthcare
Ratio P/B pour Hemostemix Inc. (HEM)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Hemostemix Inc., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Hemostemix Inc. de 2026 à 2026
Ratio P/B à la fin de chaque année
| Année | Ratio P/B | Changez |
|---|---|---|
| Pas assez de données pour les dates fournies. | ||
Ratio P/B pour des entreprises similaires ou concurrentes
| Entreprise | Ratio P/B | Différence de Ratio P/B | Pays |
|---|---|---|---|
| 6.251 | - |
US
|
|
| 13.2547 | - |
US
|
|
| 4.208 | - |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | - |
NL
|
